Business Wire

HUBILO

2.2.2021 16:20:05 CET | Business Wire | Press release

Share
Event Technology Platform Hubilo Integrates Multilingual Feature for the European Market

Event technology company Hubilo has updated its virtual event platform to include support for all the European languages, to meet the demands of a growing global market for virtual events which is expected to be worth over $400bn by 2027.

Hubilo’s platform offers customers a DIY (Do It Yourself) feature that allows them to create events based on individual specifications using a few basic steps, including customizing events in their chosen language to make the entire process simple to understand and operate. The new multilingual feature enables Hubilo to support customers across Europe better, creating a truly universal hub.

Additional Features include a networking lounge where attendees can connect and video chat with the ones with similar interests, virtual booths that provide businesses and promoters with a separate online space to market their products, speaker lounges where attendees can see a list of all event speakers and their sessions and register and add sessions to their event itinerary, live and on-demand sessions, surveys and polls , gamification experiences , automated registrations and ticket processes, and 24/7 customer care services.

For the organizers, there is a provision of features like analytics and insights to help them with quality lead assessments for conversions, a system of records that acts as a reference point to ensure that the organizers have a complete understanding of the attendee engagement rate and interactions along with other required insights across various touchpoints at the event, a broadcast studio which eliminates the need of an additional video conference software, at the same time shares all the tools that are provided by the external software and branded themes , here you can customize your event as per your brand guideline to deliver the precise brand messaging.

Vaibhav Jain, Founder and CEO, Hubilo said: “We launched our virtual platform to deliver a richer online experience for organizers and attendees, mirroring numerous positive features of in-person events along with the addition of a few advanced ones. We are glad that we are able to offer a more inclusive range of languages to our existing, and new as well as prospective clients across Europe. In fact, in order to comply with the European rules and regulations, Hubilo will also now host information on European clients and attendees on dedicated EU servers, within the European jurisdiction.”

Hubilo, which lists Roche, GITEX and Informa Group among its customers, managed to pivot to deliver online virtual events in February 2020, backed by a $4.5m investment led by Lightspeed Venture Partners. Hubilo covers the entire spectrum of meetings, incentives, conferences, and exhibitions (MICE) for external and internal events such as trade fairs, job fairs, award shows, annual sales meet, employee engagement initiatives, town halls, office parties and more.

About Hubilo :

Event technology Company Hubilo has created a comprehensive virtual platform that meets all the event-based requirements through the integration of numerous technology tools. They have redefined the entire marketing landscape around virtual events to unlock massive value for key stakeholders, such as CMOs, event organizers, and sponsors. Hubilo covers the entire spectrum of meetings, incentives, conferences and exhibitions (MICE) which include FMCG, BFSI, Education, Healthcare and Pharmaceutical, Information Technology and Manufacturing, as well as several other industries. Founded in 2015 and pivoted in February 2020 by Vaibhav Jain and Mayank Agarwal, in just 5 years, Hubilo's clientele is inclusive of names like United Nations, Roche, Informa Markets, Tech in Asia, Fortune, AWS, Siemens, GITEX, to name a few.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye